Skip to main content

Table 2 Treatment-emergent adverse events*

From: Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

 

Any grade

≥Grade 3

N

(%)

N

(%)

Neutropenia

30

(54)

6

(11)

Anemia

21

(38)

1

(2)

Thrombocytopenia

6

(11)

1

(2)

Nausea

33

(59)

4

(7)

Vomiting

4

(7)

1

(2)

Anorexia

39

(70)

7

(13)

Diarrhea

8

(14)

1

(2)

Fatigue

34

(61)

3

(5)

Stomatitis

5

(9)

0

(0)

Febrile neutropenia

0

(0)

0

(0)

  1. *No treatment-related death was observed